Nivolumab vs Semaglutide
Nivolumab vs Semaglutide: Overview
This comparison examines the pharmacological differences between Nivolumab and Semaglutide.
Mechanism of Action
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Semaglutide: GLP-1 receptor agonist with enhanced albumin binding for extended action.
Pharmacokinetics
Half-life: Nivolumab — 27 days; Semaglutide — 7 days.
Chemical Properties
Type: Nivolumab — Antibody; Semaglutide — Protein.